Market Research Report
Europe Metabolomics Market Forecast 2019-2027
|Europe Metabolomics Market Forecast 2019-2027|
Published: November 8, 2019
Content info: 112 Pages
Delivery time: 2-3 business days
The metabolomics market in the European region is estimated to grow at a CAGR of 12.09% during the forecasted period. The presence of highly developed countries and the rising demand for quality medications are the most important factors propelling market growth.
The European region with regard to metabolomics is segregated into Spain, Italy, Germany, the United Kingdom, France, and the Rest of Europe. The collaborations between important market players and the local governing bodies with an aim to manufacture and introduce different types of diagnostic tests and medications are projected to be beneficial for the overall market. Metabolomics is in its introductory stages in the European region, yet is gaining traction among other market regions. In a region like Italy, there is a large presence of pharmaceutical companies, along with rising investments in the R&D activities. In terms of pharmaceutical production, Italy ranks second in the European region. The rise of the aforementioned factors is estimated to propel the usage of metabolomics. The well-established healthcare further strengthens the growth prospects of the region, along with the shifting preference for personalized medicine. Countries like Germany are projected to witness positive growth with regard to the metabolomics market. This is because of the rising pharmaceutical R&D, coupled with the prevalence of various diseases in the region.
The increasing strategies by the key companies in the market are augmenting market growth. Kore Technology Limited, Bruker Corporation, Leco Corporation, Danaher Corporation (Sciex), Human Metabolome Technologies, Inc., Biocrates Life Sciences Ag, Bio-Rad Laboratories, Inc., Creative Proteomics, etc. are among the key companies of the region.